Home
Live Updates
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript : vimarsana.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.73 EPS, expectations were $-0.66. Apellis Pharmaceuticals, Inc.
Related Keywords
United States ,
American ,
America ,
Raymond James ,
Tim Sullivan ,
Tazeen Ahmad ,
Colleen Kusy ,
Salveen Richter ,
Cedric Francois ,
Jon Miller ,
Yigal Nochomovitz ,
Adam Townsend ,
Anupam Rama ,
Phil Nadeau ,
Steve Seedhouse ,
Caroline Baumal ,
Yigal Natromovitz ,
Meredith Kaya ,
European Commission ,
Citigroup ,
Macula Society ,
Apellis Pharmaceuticals Fourth Quarter ,
American Academy Of Ophthalmology Annual Meeting ,
Apellis Pharmaceuticals Inc ,
European Union ,
Committee Of Medicinal Products For Human ,
Nasdaq ,
Goldman Sachs ,
Apellis Pharmaceuticals ,
Call Transcript February ,
Senior Vice President ,
Investor Relations ,
Chief Executive Officer ,
Chief Operating Officer ,
Chief Medical Officer ,
Chief Financial Officer ,
Medicinal Products ,
Human Use ,
American Academy ,
Ophthalmology Annual ,
Kidney Week ,
Cascade Phase ,
Cold Agglutinin Disease ,
Best Skin ,
Quality Cheeses ,
vimarsana.com © 2020. All Rights Reserved.